Compounds > 1-aminotetralin
Page last updated: 2024-12-06

1-aminotetralin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-Aminotetralin (1-AT) is a **chemical compound** that plays a significant role in **neuroscientific research**.

Here's why it's important:

**1. Structural Similarity to Neurotransmitters:**

* 1-AT shares a similar chemical structure with dopamine, a crucial neurotransmitter involved in motivation, reward, and movement. This structural resemblance allows it to interact with dopamine receptors.

**2. Activity at Dopamine Receptors:**

* 1-AT is known to **activate dopamine receptors**, particularly the D2 subtype, which is associated with various neurological processes. This makes it a valuable tool for studying dopamine signaling in the brain.

**3. Research Applications:**

* **Parkinson's Disease:** 1-AT has been investigated as a potential treatment for Parkinson's disease, a neurodegenerative disorder characterized by dopamine depletion. It may help alleviate motor symptoms by stimulating dopamine receptors.
* **Addiction:** 1-AT's ability to influence dopamine signaling makes it relevant to addiction research. Understanding its effects on dopamine receptors could provide insights into the mechanisms of drug dependence and potential therapeutic strategies.
* **Neuropsychiatric Disorders:** 1-AT's interactions with dopamine pathways make it relevant to research on other neuropsychiatric disorders like schizophrenia and depression, where dopamine dysfunction is implicated.

**4. Pharmacological Research:**

* 1-AT serves as a **chemical probe** to study the function of dopamine receptors. Researchers can use it to understand how these receptors work at a molecular level.
* It's also used in the development of **new drugs** targeting dopamine receptors for various neurological and psychiatric conditions.

**5. Limitations:**

* 1-AT has **limited bioavailability**, meaning it doesn't easily cross the blood-brain barrier, which restricts its therapeutic potential.
* It can also cause **side effects** due to its interaction with other neurotransmitter systems.

**Overall, 1-aminotetralin's importance in research stems from its ability to interact with dopamine receptors, its potential therapeutic implications, and its utility as a tool for studying dopamine signaling in the brain.**

1-aminotetralin: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID18066
SCHEMBL ID40422
SCHEMBL ID4667951
SCHEMBL ID14543304
MeSH IDM0106558

Synonyms (82)

Synonym
AC-5739
nsc-30349
2217-40-5
nsc30349
aminotetralin [czech]
brn 1102357
tetrahydro-beta-naphthylamine
beta-1,2,3,4-tetrahydronaphthylamine
2-amino-1,2,3,4-tetrahydronaftalen [czech]
einecs 220-973-7
1,2,3,4-tetrahydro-1-naphthylamine, 97%
1,2,3,4-tetrahydronaphthalen-1-amine
STK397313
1-aminotetralin
1,2,3,4-tetrahydro-1-naphthylamine
1-amino-1,2,3,4-tetrahydronaphthalene
T2501
AKOS000113660
T1992
HMS1735D12
1,2,3,4-tetrahydro-naphthalen-1-ylamine
1-amino-1,2,3,4-tetrahydro-naphthalene
unii-lgx8t83g7x
4-12-00-02943 (beilstein handbook reference)
aminotetralin
A815992
o7a3gv2pnx ,
einecs 218-712-7
nsc 30349
ec 218-712-7
unii-o7a3gv2pnx
1,2,3,4-tetrahydronaphthylamine
BP-10652
FT-0602202
FT-0602203
FT-0607310
AM20060829
AB00150
AB06758
AKOS016039381
SCHEMBL40422
1,2,3,4-tetrahydro-1-naphtylamine
rac-1,2,3,4-tetrahydro-1-naphthylamine
1,2,3,4-tetrahydronaphthalen-1-ylamine
racemic 1,2,3,4-tetrahydro-1-naphthylamine
racemic 1,2,3,4-tetrahydro-1-naphtylamine
1,2,3,4-tetrahydro-1-naphthalenylamine
1-aminotetraline
rac-1,2,3,4-tetrahydro-naphthalen-1-ylamine
1,2,3,4-tetrahydro naphthyl amine
racemic 1,2,3,4-tetrahydro-l-naphthylamine
tetrahydro-1-naphthylamine
SCHEMBL4667951
1-naphthalenamine, 1,2,3,4-tetrahydro-
Q-100282
SCHEMBL14543304
1,2,3,4-tetrahydro-1-naphthalenamine #
1,2,3,4-tetrahydronaphthalene-1-amine
(+/-)-1-aminotetralin
(rs)-1,2,3,4-tetrahydro-1-naphthylamine
(+/-)-1,2,3,4-tetrahydro-.alpha.-naphthylamine
(rs)-1-aminotetralin
1-aminotetralin, (+/-)-
1-naphthalenamine, 1,2,3,4-tetrahydro-, (+/-)-
(+/-)-1,2,3,4-tetrahydro-1-naphthylamine
mfcd00671629
mfcd00001740
naphthalenamine, 1,2,3,4-tetrahydro-
CS-W007739
F0001-0783
SY001972
carbamicacid,[4(s)-(hydroxymethyl)-2-cyclopenten-1-yl]-1,1-dimethylethylester,(1r-cis)-
SY045443
s)-1-amino-1,2,3,4-tetrahydronaphthalene
BCP26855
SB13761
Q27285437
DTXSID70903059
SY004141
AS-81177
EN300-18939
PD179126
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (25.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's5 (62.50)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.39

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.39 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.39)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		7.1510isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
spiperone
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.		1.9610aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
apomorphine
Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.		1.9610aporphine alkaloidalpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug
1-phenethylamine
1-phenethylamine: RN given refers to cpd without isomeric designation. 1-phenylethylamine : A phenylethylamine that is ethylamine substituted by a phenyl group at position 1.		210phenylethylaminehuman metabolite
2-aminotetralin
2-aminotetralin: RN given refers to parent cpd without isomeric designation; structure		1.9610tetralins
phosphoramidic acid
phosphoramidic acid: urease inhibitor; RN given refers to parent cpd; structure; do not confuse with phosphoramidites, which are organophosphorus compounds		2.1110phosphoric acid derivative
2-aminoindan
[no description available]		1.9610
1-aminoindan
[no description available]		1.9610
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		2.1110divalent inorganic anion;
phosphite ion
ConditionIndicatedRelationship StrengthStudiesTrials
Encephalitis, Polio
[description not available]		02.0610
Poliomyelitis
An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)		02.0610
Astrocytoma, Grade IV
[description not available]		02.1510
Cancer of Prostate
[description not available]		02.1510
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		02.1510
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.1510